|Day Low/High||79.61 / 80.76|
|52 Wk Low/High||67.88 / 88.48|
Goldman Sachs upped Eli Lilly's (LLY) stock rating to 'buy' this morning, citing its solid pipeline.
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
One of the largest healthcare companies in the world embraces Salesforce to gain more insights about their patients and quickly build and release apps based on their needs
Rumors are swirling about Big Pharma interest in the cancer drug developer, but the validity of such theories is questioned by at least some company followers.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
I want to use a marriage of stock and ratio call spreads to create a juiced-up, covered-call approach.
Allegations that Merck breached patents on diabetes blockbuster Lantus looks like a replay of Sanofi's 2015 case against Eli Lilly.
Eli Lilly's (LLY) olaratumab drug for soft tissue sarcoma was recommended for approval by the European Medicines Agency on Friday.
Aggressive 8-point plan to help safeguard animal and human health makes progress, creates pipeline of alternatives to shared-class antibiotics
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?
I like a bearishly biased, slightly-out-of-the-money vertical put spread.
Eli Lilly's (LLY) stock rating was lifted to 'overweight' from 'neutral' at JPMorgan on Thursday morning.
Here are Thursday's top research calls, including downgrades for Apple, Lululemon Athletica, Nike and Tractor Supply.
Backed by the government, initiatives to develop and popularize non-opioid painkillers can make investors high on profits.
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
It's time to unload these toxic stocks from your portfolio.
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
AZD3293 is an oral potent small molecule BACE inhibitor in phase 3 development
Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.
Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.